Dimerix Limited announced the appointment of Dr David Fuller as Chief Medical Officer. Dr Fuller is an internationally experienced pharmaceutical executive and physician with over 30 years' experience across pre-clinical and clinical development, as well as medical and regulatory affairs, and was the former CMO of Race Oncology. Dr Fuller, who has a strong fundamental background in the Dimerix technology having worked with Dimerix prior to public listing, will be responsible for the strategic delivery of the company's flagship ACTION3 Phase 3 clinical program for focal segmental glomerulosclerosis kidney disease currently recruiting globally.
Company Information
Company
Dimerix Limited
Location
Melbourne, Victoria, Australia
About
Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
Fundz sees it the moment Dimerix Limited changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MelbourneBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma